The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 25, 2025

Filed:

May. 23, 2023
Applicant:

Exuma Biotech Corp., West Palm Beach, FL (US);

Inventors:

Gregory Ian Frost, West Palm Beach, FL (US);

James Joseph Onuffer, Jr., Alameda, CA (US);

Ghiabe H. Guibinga, San Diego, CA (US);

Farzad Haerizadeh, San Diego, CA (US);

Anirban Kundu, Grand Cayman, KY;

Assignee:

Exuma Biotech Corp., West Palm Beach, FL (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/867 (2006.01); A61K 35/17 (2015.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); A61K 48/00 (2006.01); C07K 14/005 (2006.01); C07K 14/54 (2006.01); C07K 14/705 (2006.01); C07K 14/715 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01); C12N 5/0783 (2010.01); C12N 15/10 (2006.01); C12N 15/113 (2010.01); C12N 15/33 (2006.01); C12N 15/48 (2006.01); C12N 15/86 (2006.01); C12N 15/87 (2006.01);
U.S. Cl.
CPC ...
C12N 15/86 (2013.01); A61K 39/461 (2023.05); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/464412 (2023.05); A61K 39/464499 (2023.05); A61K 39/464838 (2023.05); C07K 14/005 (2013.01); C07K 14/5418 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 14/70578 (2013.01); C07K 14/70596 (2013.01); C07K 14/7155 (2013.01); C07K 16/2803 (2013.01); C07K 16/2809 (2013.01); C07K 16/2818 (2013.01); C07K 16/283 (2013.01); C07K 16/2863 (2013.01); C07K 16/30 (2013.01); C07K 16/32 (2013.01); C12N 5/0636 (2013.01); C12N 5/0646 (2013.01); C12N 15/1048 (2013.01); C12N 15/113 (2013.01); C12N 15/1138 (2013.01); A61K 2039/572 (2013.01); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05); C07K 2317/622 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/31 (2013.01); C07K 2319/32 (2013.01); C07K 2319/33 (2013.01); C12N 2310/12 (2013.01); C12N 2310/121 (2013.01); C12N 2310/141 (2013.01); C12N 2310/16 (2013.01); C12N 2310/531 (2013.01); C12N 2510/00 (2013.01); C12N 2740/10043 (2013.01); C12N 2740/10045 (2013.01); C12N 2740/10052 (2013.01); C12N 2740/16043 (2013.01); C12N 2740/16052 (2013.01); C12N 2760/18422 (2013.01); C12N 2800/30 (2013.01); C12N 2830/002 (2013.01); C12N 2830/008 (2013.01); C12N 2840/203 (2013.01);
Abstract

The present disclosure provides methods for genetically modifying lymphocytes and methods for performing adoptive cellular therapy that include transducing T cells and/or NK cells. The methods can include inhibitory RNA molecule(s) and/or engineered signaling polypeptides that can include a lymphoproliferative element, and/or a chimeric antigen receptor (CAR), for example a microenvironment restricted biologic CAR (MRB-CAR). Additional elements of such engineered signaling polypeptides are provided herein, such as those that drive proliferation and regulatory elements therefor, as well as replication incompetent recombinant retroviral particles and packaging cell lines and methods of making the same. Numerous elements and methods for regulating transduced and/or genetically modified T cells and/or NK cells are provided, such as, for example, those including riboswitches, MRB-CARs, recognition domains, and/or pH-modulating agents.


Find Patent Forward Citations

Loading…